Stockscreener 앱 받기
8.31
1.66%
-0.14
전일 마감가:
$8.45
열려 있는:
$8.66
하루 거래량:
500.34K
Relative Volume:
1.51
시가총액:
$468.97M
수익:
-
순이익/손실:
$-72.89M
주가수익비율:
-3.4339
EPS:
-2.42
순현금흐름:
$-68.47M
1주 성능:
+10.51%
1개월 성능:
+10.95%
6개월 성능:
+104.68%
1년 성능:
-20.86%
1일 변동 폭
$7.85
$8.69
1주일 범위
$7.3566
$8.69
52주 변동 폭
$3.555
$12.52
Astria Therapeutics Inc Stock (ATXS) Company Profile
명칭
Astria Therapeutics Inc
전화
617-349-1971
주소
22 BOSTON WHARF ROAD, BOSTON
ATXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
8.31 | 476.87M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-29 | 개시 | TD Cowen | Buy |
| 2023-03-28 | 개시 | Evercore ISI | Outperform |
Astria Therapeutics Inc 주식(ATXS)의 최신 뉴스
Is it too late to sell Astria Therapeutics Inc.Swing Trade & Expert Verified Stock Movement Alerts - newser.com
3 Biotech Stocks That Could More Than Triple if Their Trials Succeed - MSN
Can Astria Therapeutics Inc. stock sustain institutional interest2025 Market Outlook & High Conviction Buy Zone Alerts - newser.com
Comparing Astria Therapeutics Inc. in custom built stock radars2025 Retail Activity & Verified Entry Point Signals - newser.com
How to forecast Astria Therapeutics Inc. trends using time seriesWeekly Gains Report & Consistent Profit Alerts - newser.com
Visual analytics tools that track Astria Therapeutics Inc. performanceJuly 2025 Institutional & Scalable Portfolio Growth Methods - newser.com
Tick level data insight on Astria Therapeutics Inc. volatility2025 Winners & Losers & Technical Entry and Exit Tips - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat
H.C. Wainwright reiterates Buy rating on Astria Therapeutics stock at $20 - Investing.com Canada
Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting - Business Wire
Analyzing Astria Therapeutics Inc. with multi timeframe chartsEarnings Risk Summary & Reliable Price Breakout Signals - newser.com
How to interpret RSI for Astria Therapeutics Inc. stock2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com
Astria Therapeutics begins phase 3 long-term trial for HAE treatment - Investing.com Nigeria
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with - PharmiWeb.com
Astria Therapeutics (ATXS) Begins Phase 3 Trial for Hereditary A - GuruFocus
Astria Therapeutics initiates the phase 3 ORBIT-EXPANSE long-term trial of navenibart in people with hereditary angioedema - MarketScreener
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema - FinancialContent
Astria Therapeutics, Inc. $ATXS Stock Position Lifted by Farther Finance Advisors LLC - Defense World
How strong is Astria Therapeutics Inc. stock balance sheetJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
Predicting Astria Therapeutics Inc. trend using moving averages2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com
What’s the recovery path for long term holders of Astria Therapeutics Inc.Quarterly Trade Report & Fast Moving Stock Watchlists - newser.com
Using Ichimoku Cloud for Astria Therapeutics Inc. technicalsWeekly Gains Summary & Free Technical Pattern Based Buy Signals - newser.com
Will Astria Therapeutics Inc. outperform the marketRate Cut & Free Fast Gain Swing Trade Alerts - newser.com
Will breakout in Astria Therapeutics Inc. lead to full recovery2025 Analyst Calls & Capital Protection Trading Alerts - newser.com
Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA - Business Wire
Will Astria Therapeutics Inc. bounce back from current supportPortfolio Return Report & Free Technical Confirmation Trade Alerts - newser.com
Momentum divergence signals in Astria Therapeutics Inc. chartStop Loss & Growth Focused Investment Plans - newser.com
Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial - BioSpace
Astria Therapeutics expands phase 3 HAE trial to European Union By Investing.com - Investing.com Nigeria
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
Astria Therapeutics (ATXS) Advances Phase 3 Trial for Hereditary Angioedema Treatment - GuruFocus
Astria Therapeutics expands phase 3 HAE trial to European Union - Investing.com India
Astria Therapeutics Inc (ATXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.74%
자본화:
|
볼륨(24시간):